Literature DB >> 29858156

High irisin levels in overweight/obese children and its positive correlation with metabolic profile, blood pressure, and endothelial progenitor cells.

F De Meneck1, L Victorino de Souza2, V Oliveira2, M C do Franco3.   

Abstract

BACKGROUND AND AIMS: Irisin is involved in the compensatory mechanisms for metabolic regulation and appears to be associated with glucose homeostasis and lipid profile. However, it's possible implications on obesity-associated cardiometabolic complications have not been completely elucidated. This study aimed to investigate the association between irisin level and anthropometric data, metabolic parameters, blood pressure, and endothelial progenitor cells (EPCs) level among children with overweight/obesity. METHODS AND
RESULTS: This study included 24 children with overweight/obesity (9 girls and 15 boys) and 63 children with normal weight (25 girls and 38 boys). The anthropometric data, blood pressure, blood biochemistry, EPCs and irisin levels were evaluated. Children with overweight/obesity had significantly higher circulating irisin and EPCs levels than those with normal weight (P < 0.001). Additionally, we found that irisin level was positively correlated with BMI (rho = 0.407), waist circumference (rho = 0.449), triglycerides (rho = .334), glucose (rho = 0.226), insulin (rho = 0.533), HOMA (rho = 0.545), and negatively correlated with HDL cholesterol level (rho = -0.218). Importantly, we also found that irisin levels were significantly correlated with systolic (rho = 0.420), diastolic (rho = 0.331) blood pressure and circulating EPCs level (rho = 0.391).
CONCLUSION: Our study provides evidence that overweight/obese children had elevated circulating levels of both irisin and EPCs and address the gap in the literature with regard to the understanding of the implications of irisin on obesity-related cardiometabolic complications among these children and also highlight the possible involvement of irisin regulation on insulin resistance and endothelial function in childhood overweight and obesity.
Copyright © 2018 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Children; Endothelial progenitor cells; Insulin; Irisin; Overweight/obesity

Mesh:

Substances:

Year:  2018        PMID: 29858156     DOI: 10.1016/j.numecd.2018.04.009

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  17 in total

1.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

2.  Association between irisin and metabolic parameters in nondiabetic, nonobese adults: a meta-analysis.

Authors:  Yan Li; Zhenbin Xu
Journal:  Diabetol Metab Syndr       Date:  2022-10-21       Impact factor: 5.395

3.  Irisin treatment lowers levels of phosphorylated tau in the hippocampus of pre-symptomatic female but not male htau mice.

Authors:  Katie A Bretland; Li Lin; Kimberly M Bretland; Matthew A Smith; Sheila M Fleming; Christine M Dengler-Crish
Journal:  Neuropathol Appl Neurobiol       Date:  2021-05-05       Impact factor: 6.250

4.  Superiority of the Non-Glycosylated Form Over the Glycosylated Form of Irisin in the Attenuation of Adipocytic Meta-Inflammation: A Potential Factor in the Fight Against Insulin Resistance.

Authors:  Agnieszka Irena Mazur-Bialy
Journal:  Biomolecules       Date:  2019-08-21

5.  Myokine-adipokine cross-talk: potential mechanisms for the association between plasma irisin and adipokines and cardiometabolic risk factors in Mexican children with obesity and the metabolic syndrome.

Authors:  Adrian M Gonzalez-Gil; Mariana Peschard-Franco; Elena C Castillo; Gustavo Gutierrez-DelBosque; Victor Treviño; Christian Silva-Platas; Luisa Perez-Villarreal; Gerardo Garcia-Rivas; Leticia Elizondo-Montemayor
Journal:  Diabetol Metab Syndr       Date:  2019-08-05       Impact factor: 3.320

Review 6.  Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases.

Authors:  Paulina Korta; Ewa Pocheć; Agnieszka Mazur-Biały
Journal:  Medicina (Kaunas)       Date:  2019-08-15       Impact factor: 2.430

7.  The Effect of Pubertal Stage on the Concentrations of the Novel Adipomyokine, Irisin, in Male Adolescents

Authors:  Demet Taş; Alkım Akman Öden; Sinem Akgül; Ziya E. Metin; Aslı Pınar; Nuray Kanbur
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-09-13

Review 8.  Irisin and Autophagy: First Update.

Authors:  Mirko Pesce; Patrizia Ballerini; Teresa Paolucci; Iris Puca; Mohammad Hosein Farzaei; Antonia Patruno
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

9.  The Effect of a Life-Style Intervention Program of Diet and Exercise on Irisin and FGF-21 Concentrations in Children and Adolescents with Overweight and Obesity.

Authors:  Sofia I Karampatsou; Sofia M Genitsaridi; Athanasios Michos; Eleni Kourkouni; Georgia Kourlaba; Penio Kassari; Yannis Manios; Evangelia Charmandari
Journal:  Nutrients       Date:  2021-04-13       Impact factor: 5.717

10.  Serum Irisin Levels, Endothelial Dysfunction, and Inflammation in Pediatric Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

Authors:  Anna S Huerta-Delgado; Daniel N Roffe-Vazquez; Adrian M Gonzalez-Gil; José R Villarreal-Calderón; Oscar Tamez-Rivera; Nora A Rodriguez-Gutierrez; Elena C Castillo; Christian Silva-Platas; Gerardo Garcia-Rivas; Leticia Elizondo-Montemayor
Journal:  J Diabetes Res       Date:  2020-09-04       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.